Effect of Aronia melanocarpa fruit juice on indomethacin-induced gastric mucosal damage and oxidative stress in rats.
Aronia melanocarpa fruits are rich in phenolic substances-mainly flavonoids from the anthocyanin subclass. The anthocyanins are water-soluble plant pigments with antioxidant, anti-inflammatory, antimicrobial, hepatoprotective, gastroprotective and other activities. We studied the effect of A. melanocarpa fruit juice (AMFJ) on indomethacin-induced gastric mucosal damage in rats and its possible relation to the oxidative status. AMFJ (5, 10 and 20 ml kg(-1)) was applied orally as a pretreatment 1 h before the subcutaneous administration of indomethacin (30 mg kg(-1)). Gastric ulcer formation was estimated morphometrically and histopathologically 4h after the indomethacin administration. Malondialdehyde (MDA) in rat plasma and gastric mucosa and also reduced glutathione (GSH) and oxidized glutathione (GSSG) in gastric mucosa were determined and used as biochemical markers of the oxidative status. AMFJ-pretreatment diminished the number and area of indomethacin-induced gastric lesions. Histopathological examination of rat stomachs demonstrated that AMFJ induced an increase in gastric mucus production and a reduction of the depth and severity of indomethacin-induced mucosal lesions. AMFJ dose-dependently reduced the elevated indomethacin plasma and gastric MDA levels and at the doses of 10 and 20 ml kg(-1) they were not significantly different from the control values. Neither indomethacin-treatment, nor AMFJ-pretreatment had a significant influence on GSH and GSSG gastric mucosal levels. These results demonstrated that indomethacin-induced gastric mucosal damage was accompanied by the development of oxidative stress, evidenced by the accumulation of MDA. AMFJ-pretreatment decreased the gastric lesions caused by indomethacin. It could be suggested that this effect of AMFJ was probably due to the increased mucus production and interference with oxidative stress development as evidenced by the decreased plasma and gastric mucosal MDA.
Valcheva-Kuzmanova
S
S
Department of Preclinical and Clinical Pharmacology and Biochemistry, Medical University, 55 Marin Drinov Str., 9002 Varna, Bulgaria. stefkavk@yahoo.com
Marazova
K
K
Krasnaliev
I
I
Galunska
B
B
Borisova
P
P
Belcheva
A
A
D000284:Administration, Oral; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D015415:Biomarkers / Q000378:metabolism; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005753:Gastric Mucosa / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D005978:Glutathione / Q000378:metabolism; D019803:Glutathione Disulfide / Q000378:metabolism; D007213:Indomethacin / Q000633:toxicity*; D007279:Injections, Subcutaneous; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D018384:Oxidative Stress / Q000187:drug effects*; D046936:Photinia / Q000737:chemistry*; D010936:Plant Extracts / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D013276:Stomach Ulcer / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*
D000975:Antioxidants; D015415:Biomarkers; D010936:Plant Extracts; D008315:Malondialdehyde; D005978:Glutathione; D019803:Glutathione Disulfide; D007213:Indomethacin